Shen C, Ma Y, Zeng Z, Yin Q, Hong Y, Hou X, et al
Kahal, H., Kilpatrick, E., Rigby, A., Coady, A
If you encounter any of these side effects or any other unusual symptoms, it is advisable to contact your healthcare provider immediately
6 Multi-agonist strategies are increasingly being studied, some of which include dual GLP-1/GIP agonists like tirzepatide and triple agonists that target GLP-1, GIP, and glucagon-like retatrutide
Due to the short half-life of endogenous, clinical applications rely on structurally modified
Additionally, processes involving kappa kinase (IKK-), c-Jun N-terminal kinase (JNK-1), protein kinase C (PKC), and mammalian target of rapamycin (mTOR)-driven serine modification of IRS1 also contribute to insulin resistance, further intensified by free fatty acids, lipotoxicity, oxidative stress, and inflammation (Stergios et al., 2009)